Back to the future for antiparasite vaccines?

Expert Review of Vaccines

Volumn 12, Issue 1, 2013, Pages 1-4

  Loukas, Alex ^a   Good, Michael F ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

hookworm; irradiated; malaria; parasite; schistosome; subunit; vaccine

Indexed keywords

AMA1 VACCINE; MALARIA VACCINE; MSP1 VACCINE; PARASITE VACCINE; SM TSP 2 VACCINE; SM14 VACCINE; UNCLASSIFIED DRUG; VACCINE;

DRUG EFFICACY; HELMINTHIASIS; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INNATE IMMUNITY; MALARIA; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; REVIEW; SCHISTOSOMIASIS;

ANCYLOSTOMATOIDEA; ANIMALS; HELMINTHIASIS; HUMANS; MALARIA; PLASMODIUM; SCHISTOSOMA; VACCINES; VACCINES, ATTENUATED;

EID: 84871575257     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.136     Document Type: Review

References (23)

1. Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat. Rev. Microbiol. 9(12), 889-893 (2011).
2. Unnikrishnan M, Rappuoli R, Serruto D. Recombinant bacterial vaccines. Curr. Opin. Immunol. 24(3), 337-342 (2012).
3. Di Giulio G, Lynen G, Morzaria S, Oura C, Bishop R. Live immunization against East Coast fever-current status. Trends Parasitol. 25(2), 85-92 (2009).
4. De Vos AJ, Bock RE. Vaccination against bovine babesiosis. Ann. NY Acad. Sci. 916, 540-545 (2000).
5. Miller TA. Vaccination against the canine hookworm diseases. Adv. Parasitol. 9, 153-183 (1971).
6. Kemp DJ, Coppel RL, Cowman AF, Saint RB, Brown GV, Anders RF. Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans. Proc. Natl Acad. Sci. USA 80(12), 3787-3791 (1983).
7. Agnandji ST, Lell B, Soulanoudjingar SS et al.; RTS,S Clinical Trials Partnership. First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365(20), 1863-1875 (2011).
8. Barry AE, Schultz L, Buckee CO, Reeder JC. Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS ONE 4(12), e8497 (2009).
9. Epstein JE, Tewari K, Lyke KE et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334(6055), 475-480 (2011).
10. Butler NS, Vaughan AM, Harty JT, Kappe SH. Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol. 33(5), 247-254 (2012).
11. Roestenberg M, McCall M, Hopman J et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361(5), 468-477 (2009).
12. Pinzon-Charry A, McPhun V, Kienzle V et al. Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. J. Clin. Invest. 120(8), 2967-2978 (2010).
13. Aly AS, Downie MJ, Mamoun CB, Kappe SH. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice. Cell. Microbiol. 12(7), 930-938 (2010).
14. Miller TA. Industrial development and field use of the canine hookworm vaccine. Adv. Parasitol. 16, 333-342 (1978).
15. Kariuki TM, Van Dam GJ, Deelder AM et al. Previous or ongoing schistosome infections do not compromise the efficacy of the attenuated cercaria vaccine. Infect. Immun. 74(7), 3979-3986 (2006).
16. Genton B, Betuela I, Felger I et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185(6), 820-827 (2002).
17. Good MF. Our impasse in developing a malaria vaccine. Cell. Mol. Life Sci. 68(7), 1105-1113 (2011).
18. Sirima SB, Cousens S, Druilhe P. Protection against malaria by MSP3 candidate vaccine. N. Engl. J. Med. 365(11), 1062-1064 (2011).
19. Riveau G, Deplanque D, Remoué F et al. Safety and immunogenicity of rSh28GST antigen in humans: Phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl. Trop. Dis. 6(7), e1704 (2012).
20. Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat. Rev. Microbiol. 8(11), 814-826 (2010).
21. Diemert DJ, Pinto AG, Freire J et al. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. J. Allergy Clin. Immunol. 130(1), 169-176.e6 (2012).
22. Gaze S, McSorley HJ, Daveson J et al. Characterising the mucosal and systemic immune responses to experimental human hookworm infection. PLoS Pathog. 8(2), e1002520 (2012).
23. Feary J, Venn A, Brown A et al. Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study. Clin. Exp. Allergy 39(7), 1060-1068 (2009).